SCHEMBL27094582

SCHEMBL27094582

C[C@@H]1C[C@H](CNC(=O)O)c2ncccc2O1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 4/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ HTT P42858 2/20 0.36
▸ TSHR P16473 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ BLM P54132 1/20 0.36
▸ AKR1B1 P15121 2/20 0.34
▸ HPGD P15428 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ P2RX7 Q99572 3/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ MTNR1A P48039 1/20 0.33
▸ CACNA1G O43497 1/20 0.33
▸ CACNA1H O95180 1/20 0.33
▸ CACNA1I Q9P0X4 1/20 0.33
▸ AIMP2 Q13155 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27094593 1.00 GAA (0.38) GAAMEN1KMT2AL3MBTL1HTT
SCHEMBL27094485 1.00 GAA (0.38) GAAMEN1KMT2AL3MBTL1HTT
SCHEMBL27094488 0.85 HTT (0.41) GAAMEN1KMT2AL3MBTL1HTT
SCHEMBL27094530 0.85 HTT (0.41) GAAMEN1KMT2AL3MBTL1HTT
SCHEMBL27094529 0.84 AKR1B1 (0.39) GAAMEN1KMT2AL3MBTL1HTT
SCHEMBL30030597 0.83 ACACB (0.40) GAAMEN1KMT2AL3MBTL1HTT
SCHEMBL30030986 0.83 ACACB (0.40) GAAMEN1KMT2AL3MBTL1HTT
SCHEMBL30030896 0.83 ACACB (0.40) GAAMEN1KMT2AL3MBTL1HTT
SCHEMBL27094487 0.82 KDM4E (0.40) GAAMEN1KMT2AL3MBTL1HTT
SCHEMBL27094572 0.82 KDM4E (0.40) GAAMEN1KMT2AL3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228505-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2024-07-11 — — US disclosed
US-20240150370-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2024-05-09 — — US disclosed
EP-4324834-A1 BICYCLIC PYRIDINE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2024-02-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228505-A1 BICYCLIC PYRIDINE DERIVATIVE CBR1, CBR3, CYB5R3 GAA 4693/4885MEN1 4030/4885KMT2A 1562/4885
US-20240150370-A1 BICYCLIC PYRIDINE DERIVATIVE CBR1, CBR3, CYB5R3 GAA 4693/4885MEN1 4030/4885KMT2A 1562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback